A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
NCT07840326
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Primary Progressive Multiple Sclerosis
- Primary Progressive MS
- Primary Progressive Multiple Sclerosis (PPMS)
- Secondary Progressive MS (SPMS)
- Secondary Progressive Multiple Sclerosis (SPMS)
- Secondary Progressive MS
- Non-Active SPMS
- Non-Active Secondary Progressive Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Sundance Biosciences, Inc.
- Last updated on ClinicalTrials.gov
- September 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Georgia · 1
- Local Institution - Site 102 · Atlanta, GA
North Carolina · 1
- Local Institution - Site 101 · Raleigh, NC
Ohio · 1
- Local Institution - Site 104 · Columbus, OH
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.